Maintenance sunitinib (MS) or observation (O) in metastatic pancreatic adenocarcinoma (MPA): Clinical and translational results of a phase II randomized trial (NCT00967603).
Michele Reni
Consultant or Advisory Role - Celgene; Pfizer; Roche/Genentech
Honoraria - Celgene; Roche/Genentech
Research Funding - Novartis; PharmaMar; Roche/Genentech
Stefano Cereda
No relevant relationships to disclose
Michele Milella
No relevant relationships to disclose
Anna Novarino
No relevant relationships to disclose
Alessandro Passardi
No relevant relationships to disclose
Andrea Mambrini
No relevant relationships to disclose
Giuseppe Di Lucca
No relevant relationships to disclose
Laura Ferrari
No relevant relationships to disclose
Carmen Belli
No relevant relationships to disclose
Marco Danova
No relevant relationships to disclose
Francesca Bergamo
No relevant relationships to disclose
Enrico Franceschi
No relevant relationships to disclose
Bianca Rovati
No relevant relationships to disclose
Clara Fugazza
No relevant relationships to disclose
Domenica Ceraulo
No relevant relationships to disclose
Eugenio Villa
No relevant relationships to disclose